Medy-Tox Inc. (KOSDAQ:086900)
73,000
+4,100 (5.95%)
Sep 1, 2026, 3:30 PM KST
Medy-Tox Revenue
Medy-Tox had revenue of 68.70B KRW in the quarter ending June 30, 2026, with 11.44% growth. This brings the company's revenue in the last twelve months to 251.08B, up 7.01% year-over-year. In the year 2025, Medy-Tox had annual revenue of 247.29B with 8.17% growth.
Revenue (ttm)
251.08B
Revenue Growth
+7.01%
P/S Ratio
1.79
Revenue / Employee
357.15M
Employees
703
Market Cap
449.06B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 247.29B | 18.67B | 8.17% |
| Dec 31, 2024 | 228.62B | 7.50B | 3.39% |
| Dec 31, 2023 | 221.12B | 26.02B | 13.34% |
| Dec 31, 2022 | 195.10B | 10.23B | 5.53% |
| Dec 31, 2021 | 184.87B | 44.04B | 31.27% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| GC Corp. | 2.49T |
| Onconic Therapeutics | 82.17B |
| MEDIPOST | 74.84B |
| Komipharm International | 53.02B |
| Pharmicell | 23.94B |
| SillaJen | 10.92B |
| GI Innovation | 5.63B |
| AbClon | 5.31B |